Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabozantinib - Exelixis/Ipsen

Drug Profile

Cabozantinib - Exelixis/Ipsen

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Exelixis; Ipsen; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum; Takeda; University of Kansas Medical Center
  • Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Phase II Adrenocortical carcinoma; Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Head and neck cancer; Merkel cell carcinoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Multiple myeloma; Solid tumours
  • Phase I Colorectal cancer; Gastrointestinal cancer
  • No development reported Acute myeloid leukaemia; Astrocytoma; Cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 31 Oct 2019 Exelixis files patent infringement lawsuit against MSN Pharmaceuticals for Cabozantinib in USA
  • 18 Oct 2019 Preregistration for Renal cell carcinoma (First-line therapy, Late-stage disease) in Canada (PO) before October 2019
  • 18 Oct 2019 Registered for Renal cell carcinoma (First-line therapy, Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top